Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on August 13, 2025
Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update
Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the …
BioSig Technologies Inc. Announces Proposed Public Offering
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”) which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM) today announced its intention to offer shares of common stock (or …
Applied Therapeutics Reports Second Quarter 2025 Financial Results
- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE Phase 2/3 trial of govorestat for the treatment of CMT- …
Precipio Announces its Q2-2025 Financial Results
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “Yet another …
PharmaCorp Rx Inc. Announces New Credit Facilities With CIBC and Unveils Pharmacist Co-Ownership Financing Initiative
SASKATOON, Saskatchewan, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a credit agreement with Canadian Imperial Bank of Commerce (“CIBC”) providing the …
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and unpartnered programs Consummation of acquisition expected …
Corza Medical ouvre un laboratoire d’innovation pour les textiles biomédicaux afin d’accélérer le développement de produits FEO
TAUNTON, Royaume-Uni, 13 août 2025 (GLOBE NEWSWIRE) -- Corza Medical, l’un des principaux fabricants mondiaux de technologies chirurgicales et de composants de dispositifs médicaux, a annoncé aujourd’hui l’ouverture de son laboratoire d’innovation pour les …
Corza Medical eröffnet Innovationslabor für biomedizinische Textilien zur Beschleunigung der OEM-Produktentwicklung
TAUNTON, Großbritannien, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Corza Medical, ein weltweit führender Hersteller chirurgischer Technologien und Komponenten für medizinische Geräte, hat heute die Eröffnung seines Innovationslabors für biomedizinische Textilien …
rYojbaba Co., Ltd. Announces Pricing of $5 Million Initial Public Offering of Japanese Common Shares and Listing on Nasdaq
FUKUOKA, Japan, Aug. 13, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, today announced the pricing of its initial public offering of 1,250,000 Japanese common shares at …
2025 Winners of the 31st-Annual Eric Dostie Memorial College Scholarship Announced
TEMECULA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nufactor®, a specialty infusion company and subsidiary of FFF Enterprises, Inc., is pleased to announce the names of its 2025 Eric Dostie Memorial College Scholarship recipients. The annual scholarship …
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as …
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and …
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - …
Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable …
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets Alvotech listed on Nasdaq Stockholm Market …
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types …
KBR Awarded an Estimated $2.459 Billion Contract to Support Astronaut Health and Performance for Space Missions
HOUSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- KBR (NYSE: KBR) announced today it has been awarded an estimated $2.459 billion NASA contract to support astronaut health, occupational health, and research that could help mitigate health risks for future human …
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- …
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 STRENGTH trial to …